Unisys provides biometric authentication for rapid COVID-19 testing solution
Unisys and Inspire Health Alliance have formed a relationship to support COVID-19 testing with biometric authentication, according to a company announcement.
Inspire offers real-time COVID-19 registration, testing and access control that it says is cost effective and scalable for organizations of all sizes. The solution includes portable point-of-care testing machines, which are operated by licensed healthcare administrators to perform antibody and antigen tests, and deliver results in less than 15 minutes.
Unisys Stealth(identity) biometric identity management software allows the individual’s identity to be verified during enrollment, ensures each test is taken by the right person, and prevents impersonation to protect personal data. Biometric identity can also be combined with a negative test result for integration into some building management systems for physical access control.
The combined solution is recommended in the announcement for offices, manufacturing facilities, transportation hubs, and schools.
“COVID-19 has had a devastating impact on people’s health, well-being and economic livelihood,” said Chris Kloes, vice president, Unisys Security Solutions. “Providing near real-time testing is a critical step in an organization’s approach to improve safety as we restart our businesses and schools. Through this arrangement, Unisys is able to complement Inspire’s robust COVID-19 testing at a scale and with the security, onsite integration and logistics management not yet seen in the market today. We are proud to join this meaningful effort and do our part to help get America back to work.”
Unisys Stealth software and security services, systems integration capabilities and onsite technical support and field services will be provided under the partnership to support testing by Inspire at a national scale, according to the announcement. Stealth(identity) was upgraded in July with multi-channel authentication.
The AFIAS Rapid COVID-19 Antibody Tests performed with the solution is based on a blood sample from a finger prick.
The antigen test is currently in the final stages of approval by the FDA. Inspire is currently taking orders of the solution for delivery the week of September 14.